Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 40, Issue 5, Pages 295-297Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2019.03.005
Keywords
-
Categories
Ask authors/readers for more resources
DNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues (Cancer Discov. 2019; https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
